Gilead Sciences (NASDAQ:GILD) announces findings from the DISCOVER trial evaluating Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP), showing significant improvements in key measures of bone and renal safety parameters in a subset of study participants who switched from Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF) for PrEP to Descovy for PrEP.
The data will be presented at the IDWeek 2019 conference being held in Washington, D.C. from October 2-6. Two sub-analyses of data will be presented.
The first 48-week study reports statistically significant improvements in key prespecified laboratory measures of kidney function. Improvements were statistically significant as early as Week 4 of the trial.